These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19519257)

  • 21. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Greenhill L; Posner K; Lerner M; Steinhoff K; Wigal T; Kapelinski A; Martinez J; Modi NB; Stehli A; Swanson J
    J Child Adolesc Psychopharmacol; 2007 Apr; 17(2):153-64. PubMed ID: 17489710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.
    Abbas R; Childress AC; Nagraj P; Rolke R; Berry SA; Palumbo DR
    Clin Ther; 2018 May; 40(5):733-740. PubMed ID: 29703430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of stimulants to treat ADHD: transdermal methylphenidate.
    Patrick KS; Straughn AB; Perkins JS; González MA
    Hum Psychopharmacol; 2009 Jan; 24(1):1-17. PubMed ID: 19051222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.
    Coghill DR; Rhodes SM; Matthews K
    Biol Psychiatry; 2007 Nov; 62(9):954-62. PubMed ID: 17543895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder.
    Ashkenasi A
    Pediatr Neurol; 2011 Dec; 45(6):381-6. PubMed ID: 22115000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting.
    Pelham WE; Waxmonsky JG; Schentag J; Ballow CH; Panahon CJ; Gnagy EM; Hoffman MT; Burrows-MacLean L; Meichenbaum DL; Forehand GL; Fabiano GA; Tresco KE; Lopez-Williams A; Coles EK; González MA
    J Atten Disord; 2011 Jan; 15(1):28-35. PubMed ID: 20439487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].
    Pan XX; Ma HW; Wan B; Dai XM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Aug; 10(4):471-4. PubMed ID: 18706164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.
    Teicher MH; Polcari A; Foley M; Valente E; McGreenery CE; Chang WW; McKay G; Midha KK
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):416-31. PubMed ID: 16958567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder.
    Corkum P; Panton R; Ironside S; Macpherson M; Williams T
    J Pediatr Psychol; 2008 May; 33(4):368-79. PubMed ID: 18056144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).
    Findling RL; Dinh S
    CNS Drugs; 2014 Mar; 28(3):217-28. PubMed ID: 24532028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
    Elia J; Wilson Z; La Porta LS; Algon SA; Prowler ML; Cartwright ST; McKenna PA; Laracy S; Takeda T; Borgmann-Winter K
    Expert Rev Clin Pharmacol; 2011 May; 4(3):311-28. PubMed ID: 22114778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.